The findings deepen our understanding that FOXM1 targeting in SCLC modulates AURKB and T cell mediated immune response, suggesting that combining FOXM1 inhibitors with chemo- and/or immunotherapy has the potential to improve clinical outcomes of this aggressive disease. This evidence concerns the gene AURKB and small cell lung carcinoma.